Renaissance Technologies LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 68,902 shares of the company's stock, valued at approximately $1,507,000. Renaissance Technologies LLC owned about 0.06% of Immunome at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. lifted its stake in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company's stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the last quarter. JPMorgan Chase & Co. grew its position in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company's stock worth $61,341,000 after buying an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA grew its position in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company's stock worth $100,643,000 after buying an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Immunome in the fourth quarter worth approximately $30,710,000. Finally, Sofinnova Investments Inc. increased its holdings in shares of Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company's stock valued at $34,765,000 after buying an additional 1,182,426 shares in the last quarter. Institutional investors own 44.58% of the company's stock.
Immunome News Roundup
Here are the key news stories impacting Immunome this week:
- Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
- Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
- Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
- Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release
Immunome Stock Performance
Shares of NASDAQ:IMNM opened at $27.99 on Thursday. The firm has a 50 day simple moving average of $21.89 and a 200 day simple moving average of $22.20. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $28.04. The company has a market cap of $3.17 billion, a PE ratio of -11.06 and a beta of 2.08.
Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, equities analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.
Analyst Ratings Changes
IMNM has been the subject of several research reports. Leerink Partners reduced their price objective on Immunome from $37.00 to $33.00 and set an "outperform" rating for the company in a research note on Friday, May 15th. HC Wainwright reaffirmed a "buy" rating on shares of Immunome in a research report on Thursday, July 9th. Wall Street Zen downgraded Immunome from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Truist Financial upped their target price on Immunome from $37.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Barclays assumed coverage on Immunome in a research note on Thursday, May 28th. They issued an "overweight" rating and a $36.00 price target on the stock. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Immunome presently has an average rating of "Moderate Buy" and an average target price of $34.64.
View Our Latest Stock Analysis on IMNM
Insider Transactions at Immunome
In other news, insider Robert Lechleider sold 55,000 shares of Immunome stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the transaction, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. The trade was a 77.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the company's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the transaction, the insider directly owned 50,366 shares in the company, valued at $1,263,682.94. The trade was a 64.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 682,310 shares of company stock valued at $15,675,566 over the last quarter. Company insiders own 7.21% of the company's stock.
About Immunome
(
Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Further Reading
Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
